BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32755156)

  • 1. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
    Wang ZJ; Zhang TT; An C; Ko AH; Tempero M; Collisson E; Yeh BM
    AJR Am J Roentgenol; 2020 Sep; 215(3):610-616. PubMed ID: 32755156
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
    Pancreas; 2019; 48(10):1360-1366. PubMed ID: 31688602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1679-1689. PubMed ID: 31728691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
    Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
    AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
    AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
    [No Abstract]   [Full Text] [Related]  

  • 7. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
    Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Fujita N; Ushijima Y; Itoyama M; Okamoto D; Ishimatsu K; Wada N; Takao S; Murayama R; Fujimori N; Nakata K; Nakamura M; Yamamoto T; Oda Y; Ishigami K
    Eur J Radiol; 2023 May; 162():110756. PubMed ID: 36907069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.
    Reinert CP; Baumgartner K; Hepp T; Bitzer M; Horger M
    Abdom Radiol (NY); 2020 Mar; 45(3):750-758. PubMed ID: 31953587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.
    Ciaravino V; Cardobi N; DE Robertis R; Capelli P; Melisi D; Simionato F; Marchegiani G; Salvia R; D'Onofrio M
    Anticancer Res; 2018 Aug; 38(8):4889-4895. PubMed ID: 30061265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Takumi K; Maemura K; Higashi M; Kamimura K; Nakajo M; Yoshiura T
    Eur Radiol; 2019 Jan; 29(1):353-361. PubMed ID: 29922930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
    Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
    Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small pancreatic ductal carcinomas on triple-phase contrast-enhanced computed tomography: enhanced rims and the pathologic correlation.
    Takaji R; Yamada Y; Matsumoto S; Kiyonaga M; Hongo N; Mori H; Hijiya N; Ohta M; Inomata M; Takaki H; Fukuzawa K; Yonemasu H
    Abdom Radiol (NY); 2018 Dec; 43(12):3374-3380. PubMed ID: 29796845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes.
    Cassinotto C; Chong J; Zogopoulos G; Reinhold C; Chiche L; Lafourcade JP; Cuggia A; Terrebonne E; Dohan A; Gallix B
    Eur J Radiol; 2017 May; 90():152-158. PubMed ID: 28583627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
    Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
    Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of pelvis CT during follow-up of patients with pancreatic adenocarcinoma.
    Bailey JJ; Ellis JH; Davenport MS; Cohan RH; Nan B; Parameswaran A; Hsu L; Sahai V; Francis IR
    Abdom Radiol (NY); 2017 Jan; 42(1):211-215. PubMed ID: 27519836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.
    Kim HJ; Park MS; Lee JY; Han K; Chung YE; Choi JY; Kim MJ; Kang CM
    Cancer Res Treat; 2019 Jan; 51(1):24-33. PubMed ID: 29397657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.
    Karabicak I; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kosaka H; Inoue K; Matsui Y; Kon M
    J Hepatobiliary Pancreat Sci; 2016 Dec; 23(12):750-755. PubMed ID: 27794194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.